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Abstract
Background: The management of osteoarthritis (OA) is unsatisfactory, as most treatments are not clinically effective
over placebo and most drugs have considerable side effects. On average, 75 % of the analgesic effect from OA
treatments in clinical trials can be attributed to a placebo response, and this response varies greatly from patient to
patient. This individual patient data (IPD) meta-analysis aims to identify placebo responders and the potential
determinants of the placebo response in OA.
Methods: This study is undertaken in conjunction with the OA Trial Bank, an ongoing international consortium
aiming to collect IPD from randomised controlled trials (RCTs) for all treatments of OA. RCTs for each treatment of
OA have been systematically searched for, and authors of the relevant trials have been contacted to request the
IPD. We will use the IPD of placebo-controlled RCTs held by the OA Trial Bank for this project. The IPD in placebo
groups will be used to investigate the placebo response according to the minimum clinically important difference
(MCID) threshold (e.g. 20 % pain reduction). Responders to placebo will be compared with non-responders to
identify predictors of response. The quality of the trials will be assessed and potential determinants will be
examined using multilevel logistic regression analyses.
Discussion: This study explores the varying magnitude of the placebo response and the proportion of participants
that experience a clinically important placebo effect in OA RCTs. Potential determinants of the placebo response
will also be investigated. These determinants may be useful for future studies as it may allow participants to be
stratified into groups based on their likely response to placebo. The results of this study may also be useful for
pharmaceutical companies, who could improve the design of their studies in order to separate the specific
treatment from the non-specific contextual (i.e. placebo) effects.
Systematic review registration: PROSPERO CRD42016033212
Keywords: Osteoarthritis, Placebo response, Individual patient data meta-analysis
* Correspondence: weiya.zhang@nottingham.ac.uk
†Equal contributors
2Academic Rheumatology, University of Nottingham, Clinical Sciences
Building, City Hospital, Nottingham NG5 1PB, UK
3Arthritis Research UK Pain Centre, Nottingham, UK
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fu et al. Systematic Reviews  (2016) 5:183 
DOI 10.1186/s13643-016-0362-x
Background
Osteoarthritis (OA) is the most common form of arthritis
worldwide [1]. People with OA often experience pain
alongside impaired mobility and participation, resulting in
reduced quality of life [2]. There is no cure for OA, and
available treatments aim to optimise pain management
using both pharmacological and non-pharmacologic mo-
dalities [3]. Of 51 currently available treatment options for
the symptomatic management of OA, most do not achieve
a minimum clinically important difference (MCID) (i.e. an
effect size ≥0.5) over placebo [4, 5]. Furthermore, most
pharmacological treatments have a number of side effects.
In contrast, research and clinical evidence show that pla-
cebo or sham interventions appear to be effective for symp-
tom control in OA [6] and in other conditions including
pain [7], depression [8], chronic fatigue syndrome [9],
asthma [10], hypertension [11], and Parkinson’s disease
[12]. Previous studies suggest that the benefits of placebo
interventions are mainly for patient symptoms and distress,
which are considered to be the principal treatment targets
in people with OA [6]. A recent meta-analysis showed that,
on average, 75 % of the analgesic effect from OA treat-
ments can be attributed to placebo response and this re-
sponse varies greatly from patient to patient [13].
However, debate continues as to whether the estimation
of placebo response is adequate and accurate. This is largely
due to the fact that the placebo response is measured as the
overall change from baseline in the placebo group [14]. It is
difficult to differentiate this from the regression to the
mean and the natural disease fluctuation unless a no-
treatment group or waiting-list group is included in the trial
[15–17]. However, Vase et al. [18] argued that the placebo
response is robust and enhances the treatment effect when
conditions are amenable to placebo, when placebo is given
as an analgesic or when participants are properly blinded
[19]. Furthermore, a systematic review [14] involving 198
randomised controlled trials (RCTs) also suggested that pla-
cebo is effective at relieving pain and improving function
and stiffness. Its effect size (ES = 0.51, 95 % CI 0.46 to 0.55)
was found to be significantly greater than that observed in
untreated, observation-only controls (ES = 0.03, 95 % CI
−0.13 to 0.18).
When studying the placebo response, it is essential to
employ correct and robust methodology. Given the fact
that predictors of placebo response may be person-specific
(e.g. age and gender) or study-specific (e.g. sample size and
allocation concealment), we need to consider both person
and study level characteristics. Individual patient data (IPD)
meta-analysis permits both individual patient level and
study level predictors of placebo response to be taken into
account. Moreover, it allows the researchers to use the
existing datasets from RCTs instead of undertaking a large
and expensive trial. This approach has been advocated by
both the European League Against Rheumatism (EULAR)
and the Osteoarthritis Research Society International
(OARSI), who have further endorsed an international col-
laboration for the development of OA Trial Bank [20]. The
OA Trial Bank is an ongoing international consortium
aiming to collect IPD from existing RCTs for all treatments
in OA. Currently, the Bank has completed an IPD analysis
for intra-articular (IA) glucocorticoids [21] and is collecting
the IPD for glucosamine, topical non-steroidal anti-
inflammatory drugs (NSAIDs), and topical capsaicin in OA.
This provides a representative sample of the treatments in
OA, spanning across various modes of delivery including
tablets, injections, and topical formulations, for this project.
The aim of this review is to identify placebo responders and
predictors of response in OA.
Methods/design
An IPD meta-analysis of RCTs will be undertaken to
identify placebo responders and to investigate the pre-
dictors of placebo response in participants with OA. In
order to increase transparency, the PRISMA-P checklist
[22] was referred to as Additional file 1.
Study selection
RCTs of IA glucocorticoids, glucosamine, topical
NSAIDs, and topical capsaicin in OA have been system-
atically searched. Placebo-controlled RCTs collected in
our IA glucocorticoids [21], glucosamine, topical
NSAID, and topical capsaicin (PROSPERO registration
number: CRD42016035254) [23] studies will be included
in this IPD analysis.
Type of studies
All placebo-controlled RCTs identified for the above four
treatments, including crossover trials, will be included. Tri-
als for other types of arthritis, such as rheumatoid arthritis,
will be excluded. Studies of non-clinical outcomes, includ-
ing biomarkers and animal models, will be excluded. No
language restrictions will be applied to this review.
Participants
Participants in the above RCTs diagnosed with OA, as de-
fined by the criteria endorsed by the American College of
Rheumatology [24, 25] or by the use of clearly defined
radiographic and clinical criteria, will be included.
Types of interventions
This review focuses on the interventions used in the con-
trol arms of trials collected in the OA Trial Bank. This in-
cludes participants receiving placebo interventions
(regardless of the mode of delivery and dose), participants
on waiting lists, and participants under standard care.
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Types of baseline assessments
As a minimum, studies will need to record pain, age, and
gender at baseline. Other clinical characteristics, including
physical function, stiffness, and pain elsewhere, will be in-
cluded if available.
Types of outcomes
The minimum criterion for inclusion is reporting of pain.
The primary outcome measure for investigating placebo re-
sponse is pain reduction at 4 weeks of follow-up. Secondary
analyses will include pain reduction at other durations of
follow-up, as well as functional impairment and patient glo-
bal assessment, as recommended by the OMERACT-
OARSI Initiative [26, 27].
Identification of eligible studies
Trials eligible for inclusion in this analysis will be identified
from the IPD collected in the OA Trial Bank for IA
glucocorticoids [21], glucosamine, topical NSAIDs, and
topical capsaicin reviews (PROSPERO registration number:
CRD42016035254) [23]. Each treatment was systematically
reviewed (MM for IA steroid, JR for glucosamine, and
MSMP for topical NSAIDs and capsaicin). The process
was similar for all reviews and is summarised below.
A search strategy was developed by the lead reviewer
and refined in consultation with team members, includ-
ing physicians, librarians, and researchers experienced in
conducting systematic reviews. A systematic literature
search was then undertaken by the lead reviewer. Data-
bases searched include Cochrane library, MEDLINE,
Embase, AMED, Web of Science, Scopus, Pedro, and
CINAHL [21]. The identified studies were exported to
Endnote, where eligibility for inclusion was assessed by
two independent reviewers. If no consensus was reached,
a third researcher was consulted.
In addition to the systematic literature search, efforts
were made to identify unpublished trials by contacting
pharmaceutical suppliers and reviewing the British
National Formulary, the electronic Medicines Compen-
dium, and Clinicaltrials.gov.
Data collection and transfer
All corresponding authors of eligible trials have been in-
vited to collaborate by MM, JR, and MSMP. Corre-
sponding authors that are interested in collaboration
have been asked to sign a data delivery agreement that
has been drafted on behalf of the OA Trial Bank. The
agreement includes items on input data, obligations,
ownership of data, terms, authorship, and publications.
Data has been contributed to the OA Trial Bank by the
corresponding author and is stored on a secure server.
Data has been accepted in any format and is kept anon-
ymised and confidential.
The corresponding authors of placebo-controlled trials
stored in the OA Trial Bank will be contacted. The au-
thors will be asked to sign a further data transfer agree-
ment allowing the use of their data for this review before
the transfer of the data to The University of Nottingham
for analysis.
Risk assessment
The quality of the included trials will be independently
assessed by two reviewers using a modified version of the
Risk of Bias tool recommended by the Cochrane Collabor-
ation [28]. Whenever there is a disagreement, a third inde-
pendent researcher will be consulted until a consensus is
reached. The modified Risk of Bias Tool is composed of
nine questions that measure each of the domains included
in the tool (Table 1). For each domain, studies will be
rated as a “low risk”, “high risk”, or “unclear risk” of bias.
Clear criteria for the ratings will be followed, and a justifi-
cation for the rating will be required. Studies will then be
categorised as “low risk”, “high risk”, or “unclear risk”. A
study with low risk is defined as fulfilling at least five of
the criteria questions.
All trials, irrespective of quality, will be included in the
primary data analyses. Subsequently, a subgroup analysis
will be undertaken to examine whether the quality of the
study influences the outcomes, for example, whether higher
quality studies have a greater placebo response.
Table 1 Modified risk of bias assessment
Yes No Unclear Comments
1. Was the randomisation procedure adequate? ☐ ☐ ☐
2. Was the treatment allocation adequately concealed? ☐ ☐ ☐
3. Were participants blinded to the intervention? ☐ ☐ ☐
4. Were physicians blinded to the intervention? ☐ ☐ ☐
5. Were outcome assessors blinded to the intervention? ☐ ☐ ☐
6. Incomplete outcome data: Is the attrition rate <15 %? ☐ ☐ ☐
7. Are all pre-specified outcomes of interest reported in the pre-specified way? ☐ ☐ ☐
8. Was intention-to-treat analysis used? ☐ ☐ ☐
9. Were the treatment and control group similar at baseline? ☐ ☐ ☐
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Data extraction
Data retrieved from the OA Trial Bank will include char-
acteristics relating to the participant (age, gender, body
mass index (BMI)); disease (radiographic information,
signs of inflammation, muscle strength, duration of com-
plaints, pain severity, type of pain, central sensitization,
psychological assessments); placebo (topical/oral/injection,
dose); trial (sample size, setting, allocation concealment,
risk of bias); and outcome measures of interest (pain,
function, patient global assessment, quality of life). All
randomised participants with a database record will be en-
tered into a pooled database, and all individual trials will
be assigned an individual trial number.
Outcomes
The primary dichotomous outcome for all analyses will be
clinically important pain relief (present/absent) at 4 weeks
after treatment. This is assessed using the visual analogue
scale (VAS) pain score from 0 (no pain) to 100 mm (worst
pain ever).
Clinically important pain relief will be defined as a 20 %
or more reduction in VAS score from baseline within the
placebo group. This threshold was chosen as it is the most
commonly used threshold for the minimum clinically
important improvement of relative change [29]. It has been
suggested for pain and function for rheumatic diseases,
including OA, and relies on the assumption that the
waiting-list or observational group has no pain reduction
[14]. In trials with a waiting-list group, significant pain relief
is defined as a reduction in pain 12.5 % greater than that
observed in the waiting-list group [30]. VAS pain score
(continuous variable) will be used for secondary analyses.
If the VAS pain score has not been measured at 4 weeks,
the time-point closest will be used instead. Pain scores at
all other time points will be considered in the secondary
analyses.
Where possible, the VAS pain score will be used for
analysis. If unavailable, the WOMAC pain score will be
used instead, followed by other Likert scores converted
into a VAS 0–100 scale [21]. Other outcomes such as
function (standardised to a 0–100 scale), global assess-
ment, and quality of life will also be considered if avail-
able [26].
Data analyses
Descriptive analyses will be performed to present the char-
acteristics of each individual trial and the study participants.
Means and standard deviations will be used to describe
normally distributed continuous data whilst medians and
interquartile ranges will be used for data that are not
normally distributed. Categorical data will be described
using frequencies and percentages. Statistical analyses will
be performed using the statistical programme Stata SE 14
(StataCorp, College Station, TX).
Any missing data will be assumed to be missing at ran-
dom (MAR); therefore, observed participant characteris-
tics will be used to impute missing data using multiple
imputation [31, 32]. Missing data will be imputed within
each original study prior to IPD being pooled. To test the
validity of the imputation, a sensitivity analysis will be car-
ried out to compare the results from the complete dataset
with those from the imputed dataset.
A one-step approach will be used as it has been dem-
onstrated to have greater power and flexibility over the
two-step approach [33]. A multilevel logistic regression
model will be fitted, taking into account the hierarchical
nature of the data. Significant pain relief will act as the
dependent variable and will be used to estimate the
magnitude of the placebo response. Random intercepts
may be introduced in the model to account for the
patients nested within each trial.
All characteristics listed in the section “Data Extraction”
(participant; disease-specific; placebo-specific; trial) will be
considered potential predictors. These have been chosen
as the current literature suggests that they are related to
pain or response to therapy in OA. Participant-related in-
formation, such as age, gender, and BMI will be used at
the patient level. Trial characteristics will be used as co-
variates at the study level. In the secondary analysis, a
time-point level will be introduced for time points other
than 4 weeks.
According to the availability of a waiting-list/no-treat-
ment control, two models will be developed. Where a
waiting list is unavailable, a multilevel logistic regression
model will be built. The dependent variable of the model
will be placebo response (yes/no), and independent vari-
ables will include all potential predictors. In terms of the
modelling strategy, we will first include all potential pre-
dictors in the model. We will then develop a model only
including significant predictors (p ≤ 0.05). Finally, we will
refine the model by re-introducing the previously ex-
cluded non-significant predictors, one by one, to examine
their significance and influence on the model.
Where a waiting list is available, predictors will be
identified by assessing the treatment-covariate inter-
action in the multilevel regression model. For this
model, the dependent variable will still be the placebo
response (yes/no). However, the independent variables
will include both the treatment (placebo yes/no) and
predictors. We will develop a model using one predictor
at a time, the treatment variable (i.e. placebo yes/no) and
the treatment-predictor interaction term. Other
predictors will be adjusted for as covariates in the model
[32, 33]. A significant predictor will be identified when
the treatment-predictor interaction term is statistically
significant (p ≤ 0.05) in the model. The overall estimate
of the effect of the predictor, with a 95 % confidence
interval and p value, will be presented.
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In addition, secondary analyses will be conducted for
VAS pain scores (continuous) using multilevel linear re-
gression models. These will be conducted as detailed
above, but the dependent variable will be replaced by VAS
score and ANCOVA (analysis of covariance) will be used
instead of the logistic regression.
The heterogeneity between trials will be tested using the
I2 value [34] and will be presented along with the 95 %
confidence interval around it [35].
The potential for publication bias and small study ef-
fects will be examined using a contour-enhanced funnel
plot and a statistical test for asymmetry [36, 37]. A p value
less than 0.10 will be taken to indicate statistical evidence
of asymmetry.
Discussion
This review aims to provide evidence of how the placebo
effect produces a clinically important improvement in
patient-centred outcomes in RCTs of OA. Potential deter-
minants of the placebo response in people with OA will be
investigated, which may be useful for future studies. Defin-
ing the patient, disease, treatment, and delivery of care-
specific factors that influences the placebo response may
allow stratification of patients who are most likely to im-
prove with placebo. As placebo effect is an integral part of
the treatment effect 13, the results of this study will be use-
ful to enhance the overall treatment effect. This study will
also help refine the effect size of placebo interventions for
pain reduction in OA, as current evidence has not allowed
a consensus on the minimum perceptible clinical improve-
ment for placebo interventions in OA [5, 29, 38].
Limitations of this review include the fact that the pla-
cebo responders are measured by the overall difference
between baseline and endpoint, rather than the difference
in effect between placebo and non-treatment groups. Fu-
ture studies may be needed to examine the magnitude of
the placebo response by comparing changes observed in
participants in placebo groups with those not receiving
treatment. As is often a limitation of IPD meta-analyses, it
is possible that original trial authors may not be willing to
collaborate or may not have access to the raw datasets re-
quired [39, 40]. Consequently, we may be underpowered
and miss some significant predictors. However, several ap-
proaches for overcoming these challenges will be imple-
mented when collecting data for the OA Trial Bank. For
example, attempts will be made to obtain IPD from trials
in the grey literature as well as directly from pharmaceut-
ical companies. We will also facilitate the process of data
collection for original authors by accepting the data in any
format [40, 41]. Finally, conducting this review within a
collaborative group like the OA Trial Bank allows pooling
of resources which aims to facilitate the process [39].
The results of this study may have implications relevant
to both clinical practice and pharmaceutical companies.
Clinicians will be made aware of the importance of the
placebo response and its determinants. This may enable
them to develop individualised treatment plans for
patients that maximise the overall treatment effect,
thereby improving symptoms and increasing patients’ sat-
isfaction. The results of this study may also be of interest
to pharmaceutical companies who could recruit partici-
pants who are likely to have a low placebo response in
their trials. This would increase the likelihood of observ-
ing a benefit for their drug over and above placebo.
Additional file
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols) 2015 checklist: recommended items
to address in a systematic review protocol*. (DOC 895 kb)
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